BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2005

View Archived Issues

Favorable results reported for pegaptanib in wet AMD and DME

Read More

AstraZeneca recaps Q1 developments

Read More

DA-7218: a novel antimycobacterial agent

Read More

AN-53 exerts antiopiate activity in vitro and in vivo

Read More

Update on the Na-ASP-2 vaccine for hookworm infection

Read More

Interferon gamma-1b found to reduce mortality in patients with IPF

Read More

AnGes inlicenses nonviral gene delivery technology from Vical

Read More

Salmedix obtains license to anticancer drug technology from Myriad Genetics

Read More

NRP-104 reaches primary and secondary endpoints in phase III ADHD trial

Read More

Razadyne ER once-daily now available

Read More

Macugen approved in Canada and Brazil

Read More

Phase II study of MN-001 in interstitial cystitis begins

Read More

Patient enrollment complete in phase IIa trial with rNAPc2 for ACS

Read More

Preclinical data on TZP-101, a novel GHS-R1a agonist, for the treatment of gastric motility disorder

Read More

Cytheris acquires license to new immunomodulating agent activating NKT cells

Read More

HCV-796 moves into phase Ib trial in hepatitis C patients

Read More

First patient treated in phase I/II trial of NF-kappaB Decoy

Read More

Isis and Pfizer form ophthalmic antisense drug discovery collaboration

Read More

IKK2 inhibitors prevent inflammatory mediator expression: potential efficacy against asthma

Read More

Antiasthma efficacy of the novel syncretic CRx-170 shown in preclinical studies

Read More

NAALADase inhibitor delays prostate cancer growth and reduces taxol-induced neuropathy in mice

Read More

Unbalanced chromosome arm 11q loss of heterozygosity predicts pediatric neuroblastoma outcome

Read More

Alcon receives approvable letter from FDA for Retaane AMD treatment

Read More

Phase II ONO-2506 study discontinued

Read More

Encysive Pharmaceuticals submits NDA for Thelin

Read More

Data on dapoxetine for premature ejaculation presented at AUA

Read More

PT-141 increases sildenafil efficacy in erectile dysfunction

Read More

Telomerase reverse transcriptase vaccination active in metastatic prostate cancer

Read More

Recent patents cover novel treatments for cognitive disorders

Read More

New agents for treating obesity disclosed by Bristol-Myers Squibb

Read More

Recent patents report novel agents for lipoprotein disorders

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 30, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing